Letter to the Editor | Open Access
Comment on “Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis”
Thanks are due to Dr. Ucak and colleagues for their valuable research evaluating the levels of serum ghrelin in patients with psoriasis . However, we wish to make some comments on methodology of their study.
Ghrelin is a hormone secreted mainly by stomach. Some types of antipsychotics, antidepressants, corticosteroids, bromocriptine, and anti-TNF-α therapy drugs were suggested to affect serum ghrelin levels [2, 3]. Also, dietary food supplements such as vitamin D and free fatty acids could affect these levels . In this respect, the authors should define whether the participants use these kinds of drugs and dietary supplements or not.
In addition, several studies revealed that certain diseases such as functional dyspepsia, celiac disease, cachexia, inflammatory bowel disease, asthma, ankylosing spondylitis, coronary artery disease, iron deficiency anemia, hepatocellular cancer, chronic liver disease, chronic renal disease, epilepsy, and Helicobacter pylori infection could affect serum ghrelin [5, 6]. The authors did not mention these contributing diseases in their paper.
Ucak and colleagues stated that they questioned the patients’ alcohol and cigarette smoking habits. As known, serum ghrelin levels are associated with alcohol intake and smoking [7, 8]. In this regard, a regression analysis could be applied for these variables to examine whether they affect serum ghrelin levels. Therefore, interpretation of results with its current form seems problematic.
In conclusion, we believe that the study of Ucak et al. contributes important data to medical literature and could lead other researchers to design a study. However clarifying above concerns will provide clearer picture to the readers.
Conflict of Interests
The authors declare no conflict of interests.
- H. Ucak, B. Demir, D. Cicek et al., “Metabolic changes and serum ghrelin level in patients with psoriasis,” Dermatology Research and Practice, vol. 2014, Article ID 175693, 6 pages, 2014.
- B. Otto, M. Tschöp, W. Heldwein, A. F. H. Pfeiffer, and S. Diederich, “Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans,” European Journal of Endocrinology, vol. 151, no. 1, pp. 113–117, 2004.
- A. Esen-Danaci, A. Sarandöl, F. Taneli, F. Yurtsever, and N. Özlen, “Effects of second generation antipsychotics on leptin and ghrelin,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1434–1438, 2008.
- L. C. Gormsen, J. Gjedsted, S. Gjedde et al., “Free fatty acids decrease circulating ghrelin concentrations in humans,” European Journal of Endocrinology, vol. 154, no. 5, pp. 667–673, 2006.
- M. S. Berilgen, B. Mungen, B. Ustundag, and C. Demir, “Serum ghrelin levels are enhanced in patients with epilepsy,” Seizure, vol. 15, no. 2, pp. 106–111, 2006.
- A. Dogan, B. Alioglu, N. Dindar, and Y. Dallar, “Increased serum hepcidin and ghrelin levels in children treated for iron deficiency anemia,” Journal of Clinical Laboratory Analysis, vol. 27, no. 1, pp. 81–85, 2013.
- D. Bouros, A. Tzouvelekis, S. Anevlavis et al., “Smoking acutely increases plasma ghrelin concentrations,” Clinical Chemistry, vol. 52, no. 4, pp. 777–778, 2006.
- J. Makovey, V. Naganathan, M. Seibel, and P. Sambrook, “Gender differences in plasma ghrelin and its relations to body composition and bone—an opposite-sex twin study,” Clinical Endocrinology (Oxford), vol. 66, no. 4, pp. 530–537, 2007.
Copyright © 2015 Mehmet Agilli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.